1. Home
  2. AKBA vs MRCO Comparison

AKBA vs MRCO Comparison

Compare AKBA & MRCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.59

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

MRCO

Mercator Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$9.87

Market Cap

226.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
MRCO
Founded
2007
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
248.3M
226.8M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
AKBA
MRCO
Price
$0.59
$9.87
Analyst Decision
Buy
Analyst Count
6
0
Target Price
★ $3.92
N/A
AVG Volume (30 Days)
★ 6.4M
41.0K
Earning Date
11-09-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 93.94
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$9.85
52 Week High
$3.19
$10.03

Technical Indicators

Market Signals
Indicator
AKBA
MRCO
Relative Strength Index (RSI) 20.35 47.62
Support Level N/A $9.86
Resistance Level $0.98 $9.90
Average True Range (ATR) 0.05 0.02
MACD -0.02 0.00
Stochastic Oscillator 4.44 5.56

Price Performance

Historical Comparison
AKBA
MRCO

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About MRCO Mercator Acquisition Corp. Class A Ordinary Shares

Mercator Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: